Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH
  • @

Browsing Tag

Susvimo

8 posts
RRoche
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
Read More

European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

  • 2026-09-21
F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is…
RRoche
Roche’s Susvimo Gets EU Approval Recommendation for nAMD
Read More

Roche’s Susvimo Gets EU Approval Recommendation for nAMD

  • 2026-07-24
Roche (OTCQX: RHHBY) announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP)…
RRoche
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Read More

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

  • 2026-07-24
F. Hoffmann-La Roche Ltd Susvimo is the first and only continuous delivery treatment that offers an alternative to…
RRoche
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Read More

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

  • 2026-07-24
F. Hoffmann-La Roche Ltd Susvimo is the first and only continuous delivery treatment that offers an alternative to…
RRoche
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Read More

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

  • 2026-07-24
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Genentech brings 45 ophthalmology abstracts to ARVO 2026

  • 2026-04-30
04/30/2026 –…
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Roche to present 45 ophthalmology studies at ARVO

  • 2026-04-30
Roche (OTCQX: RHHBY) will present more than 45 abstracts at ARVO 2026 (3–7…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche’s Contivue Earns CE Mark for Continuous Eye Disease Treatment

  • 2026-02-17
Roche (OTCQX:RHHBY) has received CE mark approval for Contivue, its Port Delivery Platform…
Switzerland
www.europesays.com